Novacyt Sa Stock Fundamentals
| NVYTF Stock | USD 0.70 0.13 22.81% |
Novacyt SA fundamentals help investors to digest information that contributes to Novacyt SA's financial success or failures. It also enables traders to predict the movement of Novacyt Pink Sheet. The fundamental analysis module provides a way to measure Novacyt SA's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novacyt SA pink sheet.
Novacyt |
Novacyt SA Company Return On Equity Analysis
Novacyt SA's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Novacyt SA Return On Equity | -0.0198 |
Most of Novacyt SA's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novacyt SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Novacyt SA has a Return On Equity of -0.0198. This is 99.92% lower than that of the Healthcare sector and 99.77% lower than that of the Medical Devices industry. The return on equity for all United States stocks is 93.61% lower than that of the firm.
Novacyt SA Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Novacyt SA's current stock value. Our valuation model uses many indicators to compare Novacyt SA value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Novacyt SA competition to find correlations between indicators driving Novacyt SA's intrinsic value. More Info.Novacyt SA is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Novacyt SA's earnings, one of the primary drivers of an investment's value.Novacyt Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novacyt SA's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Novacyt SA could also be used in its relative valuation, which is a method of valuing Novacyt SA by comparing valuation metrics of similar companies.Novacyt SA is currently under evaluation in return on equity category among its peers.
Novacyt Fundamentals
| Return On Equity | -0.0198 | |||
| Return On Asset | 0.0145 | |||
| Profit Margin | (0.1) % | |||
| Operating Margin | 0.07 % | |||
| Current Valuation | (50.49 M) | |||
| Shares Outstanding | 70.63 M | |||
| Shares Owned By Insiders | 3.49 % | |||
| Shares Owned By Institutions | 1.60 % | |||
| Price To Earning | 0.51 X | |||
| Price To Book | 0.40 X | |||
| Price To Sales | 1.04 X | |||
| Revenue | 95.78 M | |||
| Gross Profit | 64.87 M | |||
| EBITDA | (1.71 M) | |||
| Net Income | (9.73 M) | |||
| Cash And Equivalents | 99.65 M | |||
| Cash Per Share | 1.41 X | |||
| Total Debt | 1.67 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 4.66 X | |||
| Book Value Per Share | 1.88 X | |||
| Cash Flow From Operations | 15.69 M | |||
| Earnings Per Share | (0.17) X | |||
| Number Of Employees | 210 | |||
| Beta | -2.16 | |||
| Market Capitalization | 83.34 M | |||
| Total Asset | 183.7 M | |||
| Z Score | 29.4 | |||
| Net Asset | 183.7 M |
About Novacyt SA Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novacyt SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novacyt SA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novacyt SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. The company was incorporated in 2006 and is based in Vlizy-Villacoublay, France. Novacyt operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 210 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Novacyt Pink Sheet
Novacyt SA financial ratios help investors to determine whether Novacyt Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Novacyt with respect to the benefits of owning Novacyt SA security.